Menu Search
Equities

SinoMab BioScience Ltd

3681:HKG.HS

SinoMab BioScience Ltd

Actions
  • Price (HKD)1.60
  • Today's Change0.02 / 1.27%
  • Shares traded20.40k
  • 1 Year change0.00%
  • Beta--
Data delayed at least 15 minutes, as of Jul 26 2024 08:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SinoMab BioScience Ltd is a Hong Kong-based biopharmaceutical company mainly dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company primarily develops mAb-based biologics and new chemical entities (NCE). The Company’s product SM03 is a mAb for the treatment of rheumatoid arthritis (RA). The Company is developing drugs for the treatment of RA, systemic lupus erythematosus (SLE), asthma, pemphigus, sjogren’s syndrome (SS) and other immunological diseases.

  • Revenue in HKD (TTM)1.47m
  • Net income in HKD-262.46m
  • Incorporated2001
  • Employees215.00
  • Location
    SinoMab BioScience LtdUnits 303 and 305 to 307No.15 Science Park West AvenueHong Kong Hong KongHKG
  • Phone+852 34269833
  • Websitehttps://www.sinomab.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.